Alimemazine

Also known as: Trimeprazine

Active ingredient description

Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter’s antiadrenaline action. It has powerful antihistamine and anti-emetic actions. Alimemazine is used to treat neurosis, depression and anxiety of different origins. It prevents and relieves allergic conditions, which cause pruritus and urticaria by blocking histamine produced by the body during an allergic reaction. Alimemazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Alimemazine
R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AD Phenothiazine derivatives
Discover more medicines within R06AD01

Medicines

Alimemazine is the active ingredient of these drugs:

Drug
Countries

United Kingdom

Canada

France

Spain

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

76H78MJJ52 - TRIMEPRAZINE

CAS registry number

84-96-8 - alimemazine

SNOMED-CT

387471006 - Alimemazine (substance)